ES2191356T3 - Compuestos heterociclicos para la inhibicion de la secrecion de acidos gastricos, procedimientos para su preparacion y composiciones farmaceuticas de ellos. - Google Patents

Compuestos heterociclicos para la inhibicion de la secrecion de acidos gastricos, procedimientos para su preparacion y composiciones farmaceuticas de ellos.

Info

Publication number
ES2191356T3
ES2191356T3 ES98957270T ES98957270T ES2191356T3 ES 2191356 T3 ES2191356 T3 ES 2191356T3 ES 98957270 T ES98957270 T ES 98957270T ES 98957270 T ES98957270 T ES 98957270T ES 2191356 T3 ES2191356 T3 ES 2191356T3
Authority
ES
Spain
Prior art keywords
alkyl
secretion
inhibition
procedures
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98957270T
Other languages
English (en)
Inventor
Kosrat Amin
Mikael Dahlstrom
Peter Nordberg
Ingemar Starke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2191356T3 publication Critical patent/ES2191356T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de la Fórmula I **(Fórmula)** o una de sus sales farmacéuticamente aceptables, en que R1 es alquilo C1-C6; R2 es alquilo C1-C6; R3 es H o halógeno; y **(Fórmula)** es un heterociclo sustituido seleccionado entre **(Fórmula)** en que R4 es H, CH3, CH2OH o CH2CN; R5 es H o alquilo C1-C6; R6 es H, alquilo C1-C6, arilo, arilalquilo que contiene 1-2 átomos de carbono en la parte de alquilo, alquenilo C2-C6, halo(alquenilo C2-C6), alquinilo C2-C6, cicloalquilo C3-C7 o halo(alquilo C1-C6); R7 es H, halógeno, alquilo C1-C6, alquiltio C1-C6 o tiociano; n es 0 ó 1; y X es NH o O.
ES98957270T 1997-11-28 1998-11-18 Compuestos heterociclicos para la inhibicion de la secrecion de acidos gastricos, procedimientos para su preparacion y composiciones farmaceuticas de ellos. Expired - Lifetime ES2191356T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9704404A SE9704404D0 (sv) 1997-11-28 1997-11-28 New compounds

Publications (1)

Publication Number Publication Date
ES2191356T3 true ES2191356T3 (es) 2003-09-01

Family

ID=20409181

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98957270T Expired - Lifetime ES2191356T3 (es) 1997-11-28 1998-11-18 Compuestos heterociclicos para la inhibicion de la secrecion de acidos gastricos, procedimientos para su preparacion y composiciones farmaceuticas de ellos.

Country Status (32)

Country Link
US (1) US6518270B1 (es)
EP (1) EP1042324B1 (es)
JP (1) JP2001525322A (es)
KR (1) KR20010032559A (es)
CN (1) CN1142933C (es)
AR (1) AR016972A1 (es)
AT (1) ATE233263T1 (es)
AU (1) AU752187C (es)
BR (1) BR9814755A (es)
CA (1) CA2311798A1 (es)
CZ (1) CZ292349B6 (es)
DE (1) DE69811735T2 (es)
DK (1) DK1042324T3 (es)
EE (1) EE04060B1 (es)
ES (1) ES2191356T3 (es)
HU (1) HUP0100601A3 (es)
ID (1) ID24730A (es)
IL (1) IL136145A0 (es)
IS (1) IS5486A (es)
MY (1) MY121032A (es)
NO (1) NO315704B1 (es)
NZ (1) NZ504355A (es)
PL (1) PL340920A1 (es)
PT (1) PT1042324E (es)
RU (1) RU2241000C2 (es)
SE (1) SE9704404D0 (es)
SK (1) SK283904B6 (es)
TR (1) TR200001530T2 (es)
TW (1) TW515798B (es)
UA (1) UA70932C2 (es)
WO (1) WO1999028322A1 (es)
ZA (1) ZA9810468B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
SE9704404D0 (sv) 1997-11-28 1997-11-28 Astra Ab New compounds
AR025976A1 (es) 1999-10-08 2002-12-26 Affinium Pharm Inc Inhibidores de fab i.
CA2444597A1 (en) * 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Fab i inhibitors
JP2003119140A (ja) * 2001-08-08 2003-04-23 Sankyo Co Ltd ピロロピリダジン化合物を含有する医薬
CA2482991A1 (en) * 2002-04-19 2003-10-30 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines method of making and method of use thereof
WO2004022562A1 (en) 2002-09-09 2004-03-18 Cellular Genomics, Inc. 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
AU2003266622A1 (en) * 2002-09-25 2004-04-19 Sankyo Company, Limited Medicinal composition for inhibiting increase in blood gastrin concentration
AU2003266621A1 (en) * 2002-09-25 2004-04-19 Sankyo Company, Limited Medicinal composition for treatment for or prevention of visceral pain
CA2508792C (en) 2002-12-06 2013-02-05 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
US7160885B2 (en) 2003-02-10 2007-01-09 Cgi Pharmaceuticals, Inc. Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity
AR043002A1 (es) * 2003-02-18 2005-07-13 Altana Pharma Ag Imidazopirazinas 6-substituidos
WO2004082586A2 (en) * 2003-03-17 2004-09-30 Affinium Pharmaceuticals, Inc. Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
US7259164B2 (en) 2003-08-11 2007-08-21 Cgi Pharmaceuticals, Inc. Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
WO2005041961A1 (en) 2003-11-03 2005-05-12 Astrazeneca Ab Imidazo [1,2-a] pyridine derivatives for the treatment of silent gastro-esophageal reflux
CA2568914C (en) * 2004-06-04 2013-09-24 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
EP1787991B2 (en) * 2004-07-28 2020-06-24 Takeda Pharmaceutical Company Limited PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE
JP2008508347A (ja) * 2004-08-02 2008-03-21 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 5置換された1H−ピロロ[3,2−b]ピリジン
KR100946220B1 (ko) * 2004-09-03 2010-03-08 주식회사유한양행 피롤로[3,2-c]피리딘 유도체 및 그의 제조방법
PL1784402T3 (pl) 2004-09-03 2011-12-30 Yuhan Corp Pochodne pirolo[3,2-c]pirydyny oraz sposoby ich wytwarzania
US7642269B2 (en) 2004-09-03 2010-01-05 Yuhan Corporation Pyrrolo[3,2-B]pyridine derivatives and processes for the preparation thereof
DK1784404T3 (da) 2004-09-03 2012-02-13 Yuhan Corp Pyrrolo[2,3-c]pyridinderivater samt fremgangsmåder til deres fremstilling
WO2007024294A2 (en) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
WO2007028051A2 (en) 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
EP1973902A2 (en) * 2005-12-05 2008-10-01 Affinium Pharmaceuticals, Inc. 3-heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
CA2654202A1 (en) * 2006-06-06 2007-12-21 Schering Corporation Imidazopyrazines as protein kinase inhibitors
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
NZ587039A (en) 2008-02-13 2013-01-25 Gilead Connecticut Inc 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
KR101745732B1 (ko) 2008-12-08 2017-06-12 질레드 코네티컷 인코포레이티드 이미다조피라진 syk 억제제
KR101743784B1 (ko) 2008-12-08 2017-06-05 질레드 코네티컷 인코포레이티드 이미다조피라진 syk 억제제
ES2530449T3 (es) 2010-03-11 2015-03-02 Gilead Connecticut Inc Inhibidores de Syk de imidazopiridinas
SMT201900411T1 (it) 2012-06-19 2019-09-09 Debiopharm Int Sa Derivati di profaramci di (e)-n-metil-n-((3-metilbenzofuran-2-il)metil -3-(7-osso-5,6,7,8-tetraidro-1,8-naftiridin-3-il)acrilammide
SG11201600378SA (en) 2013-07-30 2016-02-26 Gilead Connecticut Inc Formulation of syk inhibitors
EA029281B1 (ru) 2013-07-30 2018-03-30 Джилид Коннектикут, Инк. Полиморф ингибиторов syk
US9687492B2 (en) 2013-12-04 2017-06-27 Gilead Sciences, Inc. Methods for treating cancers
GB201321738D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
CA2955180A1 (en) 2014-07-14 2016-01-21 Gilead Sciences, Inc. Combinations comprising entospletinib and a vinca-alkaloid for treating cancers
BR122023021456A2 (pt) 2016-02-26 2024-02-20 Debiopharm International S.A. Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
CN115028640A (zh) 2017-08-25 2022-09-09 吉利德科学公司 Syk抑制剂的多晶型物
FI3923914T3 (fi) 2019-02-14 2023-04-27 Debiopharm Int Sa Afabisiiniformulaatio, menetelmä sen valmistamiseksi
WO2020172431A1 (en) 2019-02-22 2020-08-27 Gilead Sciences, Inc. Solid forms of condensed pyrazines as syk inhibitors
MA56184A (fr) 2019-06-14 2022-04-20 Debiopharm Int Sa Afabicine pour utilisation dans le traitement d'infections bactériennes impliquant un biofilm

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507294A (en) * 1982-03-08 1985-03-26 Schering Corp. Imidazo[1,2-a]pyrazines
EP0068378B1 (en) * 1981-06-26 1986-03-05 Schering Corporation Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
US4725601A (en) 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
AU7754691A (en) * 1990-04-27 1991-11-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel pyridazines
US5041442A (en) 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
WO1992006979A1 (de) * 1990-10-15 1992-04-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue diazine
WO1993008190A1 (de) * 1991-10-25 1993-04-29 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrrolo-pyridazine mit magen- und darmschutzwirkungen
DE69529056T2 (de) * 1994-01-19 2003-11-13 Sankyo Co., Ltd. Pyrrolopyridazin-derivate
SE9602286D0 (sv) 1996-06-10 1996-06-10 Astra Ab New compounds
SE9700661D0 (sv) 1997-02-25 1997-02-25 Astra Ab New compounds
SE9704404D0 (sv) 1997-11-28 1997-11-28 Astra Ab New compounds

Also Published As

Publication number Publication date
EE200000315A (et) 2001-10-15
KR20010032559A (ko) 2001-04-25
SE9704404D0 (sv) 1997-11-28
AU752187B2 (en) 2002-09-12
PT1042324E (pt) 2003-06-30
HUP0100601A2 (hu) 2001-09-28
EE04060B1 (et) 2003-06-16
EP1042324A1 (en) 2000-10-11
TW515798B (en) 2003-01-01
RU2241000C2 (ru) 2004-11-27
EP1042324B1 (en) 2003-02-26
UA70932C2 (uk) 2004-11-15
HK1030216A1 (en) 2001-04-27
BR9814755A (pt) 2000-10-03
CN1284078A (zh) 2001-02-14
AU1356599A (en) 1999-06-16
NO20002721D0 (no) 2000-05-26
NO20002721L (no) 2000-07-28
SK6742000A3 (en) 2001-03-12
CZ292349B6 (cs) 2003-09-17
MY121032A (en) 2005-12-30
TR200001530T2 (tr) 2000-11-21
IL136145A0 (en) 2001-05-20
CN1142933C (zh) 2004-03-24
US6518270B1 (en) 2003-02-11
NZ504355A (en) 2001-12-21
PL340920A1 (en) 2001-03-12
CA2311798A1 (en) 1999-06-10
AR016972A1 (es) 2001-08-01
DK1042324T3 (da) 2003-05-05
DE69811735D1 (de) 2003-04-03
ID24730A (id) 2000-08-03
DE69811735T2 (de) 2003-12-18
IS5486A (is) 2000-05-10
JP2001525322A (ja) 2001-12-11
NO315704B1 (no) 2003-10-13
SK283904B6 (sk) 2004-04-06
AU752187C (en) 2003-09-18
HUP0100601A3 (en) 2002-10-28
ZA9810468B (en) 1999-05-21
ATE233263T1 (de) 2003-03-15
WO1999028322A1 (en) 1999-06-10
CZ20001947A3 (cs) 2000-11-15

Similar Documents

Publication Publication Date Title
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
AU7503087A (en) Amide derivatives
PL350775A1 (en) Pharmaceutical compounds
NZ334954A (en) Substituted heterocycles as anti-tumor agents
AU2492500A (en) Aspartic protease inhibitors, compositions, and associated therapeutic methods
HUP0102099A2 (hu) Szubsztituált 2-oxo-alkánsav-[2-(indol-3-il)-etil]-amid-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
IL134894A (en) 2-substituted-1,3,4,5-tetrahydro-2h-gamma-carbolines, their preparation and pharmaceutical compositions containing them
MY125562A (en) Hexahydro-pyrido (4,3-b) indole derivatives as antipsychotic drugs
EP1034783A4 (en) AMIDE DERIVATIVES
YU73202A (sh) Novi proces za sintezu n-/(s)-1-karboksibutil/-(s)- alaninskog estra i primena u sintezi perindoprila
PL335012A1 (en) Novel derivatives of indan-1-ole, method of obtaining and composition containing them
DK0775113T3 (da) N-substituerede azabicycloheptan-derivater som neuroleptika osv.
NO964216D0 (no) Ester- og karbamatderivater av azoloner som er kraftige midler mot Helicobacter
EP0812835A4 (en) OPTICALLY ACTIVE THIAZOLIDINONE DERIVATIVES
DK0412015T3 (da) Hidtil ukendte N-(23-vincristinoyl)- og N-(5-noranhydro-23-vinblastinoyl)-1-aminomethylphosphon- syrederivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
ATE266648T1 (de) Heterocyclische anthracyclinonderivate
AR004401A1 (es) Derivados de la tirosina, procedimiento para prepararlos y preparaciones farmaceuticas que los contienen.
AP2002002707A0 (en) 4, 5-Dihydro-Thiazo-2-Ylamine Derivatives and their Use as NO-Synthase Inhibitors.